Below are details about getting TriCare to pay for travel expenses to attended a medical appointment:

http://www.tricare.mil/Factsheets/viewfactsheet.cfm?id=181

TRICARE Prime and Non-Medical Attendant Travel Entitlements

Under provisions of the 2001 National Defense Authorization Act, TRICARE Prime beneficiaries referred by their primary care manager for services at a location more than 100 miles from their PCM may be eligible to have their “reasonable travel expenses” reimbursed by TRICARE. The travel reimbursement entitlement is retroactive to Oct. 30, 2000.

Eligibility for the TRICARE Prime Travel Entitlement:

The TRICARE Prime travel entitlement is available to non-active duty TRICARE Prime enrollees and TRICARE Prime Remote family members when they are referred for medically necessary, non-emergent specialty care more than 100 miles from their primary care manager location.  The “greater than 100 mile rule” is stated in statute and isn’t negotiable when determining applicability of the Prime travel benefit. 

Beneficiaries must have a valid referral and travel orders from a TRICARE representative at the military treatment facility where they are enrolled or from their TRICARE Regional Offices if their primary care manager is a TRICARE network provider. 

Note:  This entitlement doesn’t apply to expenses experienced by active duty uniformed services members, or active duty family members living with their sponsors overseas, which are reimbursed by other travel entitlements.

Reasonable Travel Expenses:

Reasonable travel expenses are the actual costs incurred by beneficiary when traveling to their specialty provider-not in an emergency status. Costs include meals, gas, tolls, parking, and tickets for public transportation (i.e. airplane, train, bus, etc.). Beneficiaries are required to submit receipts for all expenses.

Government rates will be used to estimate the reasonable cost. Beneficiaries are expected to use the least costly mode of transportation. The actual costs of lodging (including taxes and tips) and the actual cost of meals (including taxes and tips, but excluding alcoholic beverages) may be reimbursed up to the government rate for the area concerned.

General Process for Receiving Travel Reimbursement:

If the beneficiary is referred by a provider at a military treatment facility, he/she should contact a military treatment facility point-of-contact for a briefing on the entitlement process and beneficiary responsibilities.

If the beneficiary is enrolled to and referred by a civilian primary care manager, he/she should contact a point-of-contact at the TRICARE Regional Office.

Beneficiaries must obtain official travel orders from the military treatment facility or TRICARE Regional Office point-of-contact.  Beneficiaries will be required to make their own travel arrangements unless the military treatment facility or TRICARE Regional Office point-of-contact arranges for government travel. Beneficiaries are required to coordinate their own lodging arrangements.

Upon completion of travel, the expenses need to be itemized on a SF 1164 or a DD1351-2 (travel voucher) and receipts are required for all expenses.  The military treatment facility or TRICARE Regional Office point-of-contact will provide the beneficiary with specific instructions on how and where to submit his/her travel entitlement claim.

Traveling with a Non-medical Attendant:

The FY02 National Defense Authorization Act authorizes one parent, guardian or another adult family member to travel with a non-active duty Prime enrolled patient as a non-medical attendant. The non-medical attendant is authorized reimbursement of actual travel expenses. If the non-medical attendant family member is an active duty service member authorized by the military treatment facility or TRICARE Regional Office to accompany a non-active duty TRICARE Prime enrollee as a non-medical attendant, he/she is entitled to TDY allowances (per diem and mileage), not actual expenses.

If the non-medical attendant family member is a U.S. Government civilian assigned to TDY by their civilian organization, they may also be entitled to TDY allowances.

By statute, the non-medical attendant must be a parent, legal guardian or other adult family member. However, if the non-medical attendant isn’t the parent, the non-medical attendant must be at least 21 years of age. The non-medical attendant isn’t required to be enrolled in TRICARE Prime or to be TRICARE-eligible. The patient, however, must be enrolled in TRICARE Prime.

The uniformed services and the TRICARE Regional Offices have responsibility for implementing and managing the non-medical attendant provision. The non-medical attendant benefit is retroactive to December 28, 2001. Non-medical attendants that qualify for reimbursement under this entitlement should save their travel receipts.

For more information about the TRICARE Prime travel entitlement, please contact the local military treatment facility or TRICARE Regional Office beneficiary counseling and assistance coordinator or travel point-of-contact. Telephone numbers and addresses for BCACs are available on the TRICARE Web site at http://www.tricare.mil/contactus/.

Much has changed in our lives over that last two years. Travis has retired from the Marine Corps. We moved out of our old apartment into the one that we are living in now. Travis had CyberKnife radiation. Victoria started middle school. We received AMAZING NEWS that Travis’ pesky Schwannoma tumor succumbed to Dr. Adler’s treatment. NO MORE TUMOR!!!! I started back at work and went back to college.

Travis accepted his dream job at Northrop Grumman. He entered through a wonderful program called Operation Impact. Since retiring from the Marine Corps. Travis has been seeing new doctors. He struggled through Methadone withdrawal and is now 100% METHADONE FREE. He has a prescription for Vicodin to use for breakthrough pain but he has not taken any since June 30th. He has come a long way from his daily doses of 3000mg of Neurontin and 10mg of Methadone.

Our offer was accepted on our first home. (We are in escrow right now.)

Travis came down with Diverticulitis and then suffered from a secondary infection as a result of the antibiotics given to him to treat the Diverticulitis.

So much has happened over the last two years.  Life sure has not been easy but things seem to be turning around.  We are learning to see the glass as half full rather than half empty.  I expect that we will continue to face hurdles but what I have learned is there is nothing that Travis and I cannot accomplish if we put our hearts into it.

In my opinion, this is proof that CyberKnife radiation works.  It is the best treatment for a schwannoma brain tumor.  If you have a tumor or know somebody who does then ask the  doctor is CyberKnife would work for you.

I want to write more but I donated blood today and my finger is really sore from the prick.  I will try and write more soon.

You can’t ask for anymore than that.  I also got excited thinking that Travis was one of the patients included in the study.  We have not confirmed that Travis was one of the individuals discussed in the article but he will be asking his surgeon tomorrow on his visit.

I will paste the article below and a link to where I found it.

http://journals.lww.com/neurosurgery/Abstract/2009/02001/Cyberknife_Radiosurgery_for_Trigeminal_Schwannomas.4.aspx

Cyberknife Radiosurgery for Trigeminal Schwannomas
Sakamoto, Gordon T.; Borchers, D. John III; Xiao, Furen; Yang, Hee-Jin; Chang, Steven D.; Adler, John R. Jr.
Abstract
OBJECTIVE: Trigeminal schwannomas (TS) are benign tumors that are managed by surgical resection and/or stereotactic radiosurgery. Most radiosurgical series report results using the gamma knife. The CyberKnife (Accuray, Inc., Sunnyvale, CA) is a frameless, robotic stereotactic radiosurgical system. In this series, we report our experience using the CyberKnife in the treatment of TS.
METHODS: We retrospectively reviewed the medical records and diagnostic imaging in 13 consecutive patients with TS who were treated with the CyberKnife from 2003 to 2007. Seven patients had a previous surgical resection. The mean tumor volume was 6.3 mL (range, 0.39-19.98 mL), and the mean marginal dose was 18.5 Gy. Six of the tumors were treated in a single session. The mean clinical follow-up period was 21.8 months (range, 7-53 months).
RESULTS: In this series, the tumor control rate was 100%. The average reduction in tumor volume was 45% (range, 14-98%). A modest improvement in facial pain was noted in 4 of the 6 patients who presented with this symptom. One patient had improvement in facial numbness, and another had improvement in pretreatment headaches. One patient developed jaw weakness and facial dysesthesia, and another patient developed asymptomatic radiation necrosis.
CONCLUSION: Although the length of follow-up is limited, we report our initial experience with CyberKnife treatment of TS. Our results demonstrate tumor control rates and clinical outcomes that parallel those of previous reports using gamma knife radiosurgery; however, long-term follow-up studies are needed.